AI strategy for pharmaceutical companies. Deliver EBITDA impact with agentic AI.

1. Time-to-market pressure: Agentic AI can increase EBITDA by 2–4 percentage points over three to five years. Pharmaceutical companies that fall behind lose patent windows and market position to competitors deploying AI structurally.

2. Clinical trial inefficiency: Patient finding and onboarding for clinical trials is time-intensive and costly. AI can fundamentally accelerate this — but requires governance that meets EMA and GxP standards.

3. Regulatory complexity: EU AI Act + MDR + GxP = a triple compliance matrix. Every AI system must satisfy three regulatory frameworks simultaneously. Most pharmaceutical teams lack the expertise to navigate this.

4. Commercial effectiveness: Personalised HCP engagement requires AI that goes beyond traditional marketing tools. But personalisation in the pharmaceutical context touches on medical claims and advertising regulation.

The pharmaceutical industry stands at an inflection point. Agentic AI — systems that autonomously execute tasks within defined parameters — can increase EBITDA by 2–4 percentage points. That is not a marginal improvement; it is a fundamental shift in how pharmaceutical companies create value.

But the regulatory complexity is unique. No other sector navigates a triple compliance matrix of EU AI Act, MDR and GxP. Every AI system must satisfy three frameworks simultaneously — and regulators (EMA, CBG) are still developing their expectations.

Pharmaceutical companies investing now in governance-grade AI implementation — not as a compliance exercise but as strategic competitive advantage — are building a lead that is difficult to close.

AlphaIndigo practitioners combine sector experience in healthcare and life sciences with certified AI governance expertise. Our team operates as embedded leaders — not external advisers who leave reports behind.

Meet the team →